Event Description
Fecal Microbiota Transplantation (FMT) has emerged as an important yet controversial therapy for Clostridium difficile (C. difficile), a painful and sometimes life-threatening form of colitis. While there is a great deal of enthusiasm about the treatment, there remain many unanswered questions. Dr. Kahn described her pioneering work using FMT with pediatric patients and outlined critical ethical, social, and regulatory issues, including implications of the FDA’s decision to designate FMT as both a biologic and a drug.
Co-sponsored by the University of Minnesota’s BioTechnology Institute and the Microbiota Therapeutics Program
Commentator
Dr. Byron Vaughn, MD, Microbiota Therapeutics Program, University of Minnesota
Continuing Education Information
Attorneys: 1.5 standard CLE credits are approved. Event ID: 215667.
American Medical Association/PRA: The University of Minnesota is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians: The University of Minnesota designates this live educational activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Other Health Care Professionals: Research coordinators, nurse practitioners, nurses, and other health care professionals who participate in this CE activity may submit their Statements of Participation to their appropriate accrediting organizations or state boards for consideration of credit. The participant is responsible for determining whether this activity meets the requirements for acceptable continuing education.